Media Thread, page-15453

QUESTION ON THE STATUS OF HER-VAXX

In the IMU is NOT a multi-bagger thread - there was a good question, which did not get answered - probably because of the name of the thread keeps serious people away from it. Anyways -

A poster asked about the status of HER-VAXX. The conclusion of the HER-VAXX stage 2 trial was "data demonstrate that in patients with HER2 over-expressing gastric/GEJ cancer active HER2 immunization with HER-Vaxx is safe and provides relevant clinical benefit over standard of care chemotherapy". HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis. | Journal of Clinical Oncology (ascopubs.org)

I have not followed the story and I don't know exactly why HER-VAXX not been pushed into phase 3 or sold or at least put into some sort of JV and monetised. I get that IMU is now really focussing on T cells and Oncarlytics - but I don't find IMU's published information on HER-VAXX clear at all.

Can one of the few serious posters on the forum give an answer?